Olema Pharmaceuticals (OLMA) Non Operating Income (2020 - 2026)

Olema Pharmaceuticals (OLMA) has reported Non Operating Income for 7 consecutive years, with $4.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Non Operating Income rose 9.21% year-over-year to $4.9 million; the TTM figure through Mar 2026 stood at $16.7 million (up 19.86% YoY), while the FY2025 annual figure was $16.2 million, up 27.09% from the prior year.
• Non Operating Income improved to $4.9 million in Q1 2026 per OLMA's latest filing, from $4.0 million in the prior quarter.
• Across five years, Non Operating Income topped out at $4.9 million in Q1 2026 and bottomed at $224000.0 in Q1 2022.
• Historically, Non Operating Income has averaged $2.6 million across 5 years, with a median of $3.1 million in 2024.
• Annual changes were most pronounced in 2022 — Non Operating Income surged 924.49% — and 2024, when it slipped 12.16%.
• Olema Pharmaceuticals' Non Operating Income stood at $1.0 million in 2022, then surged by 250.38% to $3.6 million in 2023, then retreated by 12.16% to $3.2 million in 2024, then increased by 25.68% to $4.0 million in 2025, then rose by 21.73% to $4.9 million in 2026.
• Business Quant data shows OLMA's Non Operating Income at $4.9 million in Q1 2026, $4.0 million in Q4 2025, and $3.7 million in Q3 2025.